Larimar Therapeutics (STU:ZA71) Marketable Securities : €126.17 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Larimar Therapeutics's Marketable Securities for the quarter that ended in Mar. 2025 was €126.17 Mil.

Larimar Therapeutics's annual Marketable Securities declined from Dec. 2022 (€86.47 Mil) to Dec. 2023 (€55.06 Mil) but then increased from Dec. 2023 (€55.06 Mil) to Dec. 2024 (€143.48 Mil).

Larimar Therapeutics Marketable Securities Historical Data

The historical data trend for Larimar Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Marketable Securities Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

20.13

86.47

55.06

143.48

Larimar Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															107.80	180.00	151.95	143.48	126.17

Larimar Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Larimar Therapeutics (STU:ZA71) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Larimar Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

LRMR:USA

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines